Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

OpenVariant: a toolkit to parse and operate multiple input file formats

  • Martínez-Millán, David
  • Brando, Federica
  • Grau, Miguel L.
  • Sánchez-Guixé, Mònica
  • López Elorduy, Carlos
  • Reyes-Salazar, Iker
  • Deu-Pons, Jordi
  • López Bigas, Núria
  • González-Pérez, Abel
Summary: Advances in high-throughput DNA sequencing technologies and decreasing costs have fueled the identification of small genetic variants (such as single nucleotide variants and indels) across tumors. Despite efforts to standardize variant formats and vocabularies, many sources of variability persist across databases and computational tools that annotate variants, hindering their integration within cancer genomic analyses. In this context, we present OpenVariant, an easily extendable Python package that facilitates seamless reading, parsing and refinement of diverse input file formats in a customizable structure, all within a single process. Availability and implementation: OpenVariant is an open-source package available at https://github.com/bbglab/openvariant. Documentation may be found at https://openvariant.readthedocs.io., N.L.-B. acknowledges funding from the European Research Council [consolidator grant 682398]. This project has received funding from the European Union’s Horizon Europe programme [grant agreement CGI-Clinics 101057509]. IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and an Excellence Institutional grant by the Asociación Española contra el Cancer, and is supported by CERCA (Generalitat de Catalunya). This work has also been funded by the Institute of Health Carlos III [project IMPaCT-Data, exp. IMP/00019], co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Five latent factors underlie response to immunotherapy

  • Usset, Joseph
  • Rosendahl Huber, Axel
  • Andrianova, Maria A.
  • Batlle Gómez, Eduard
  • Carles, Joan
  • Cuppen, Edwin
  • Elez, Elena
  • Felip, Enriqueta
  • Gómez Rey, Marina
  • Lo Giacco, Deborah
  • Martínez Jiménez, Francisco
  • Muñoz Couselo, Eva
  • Siu, Lillian L.
  • Tabernero Cartula, Josep
  • Vivancos Prellezo, Ana
  • Muiños, Ferran
  • González-Pérez, Abel
  • López Bigas, Núria
Only a subset of patients treated with immune checkpoint inhibitors (CPIs) respond to the treatment, and distinguishing responders from non-responders is a major challenge. Many proposed biomarkers of CPI response and survival probably represent alternative measurements of the same aspects of the tumor, its microenvironment or the host. Thus, we currently ignore how many truly independent biomarkers there are. With an unbiased analysis of genomics, transcriptomics and clinical data of a cohort of patients with metastatic tumors (n = 479), we discovered five orthogonal latent factors: tumor mutation burden, T cell effective infiltration, transforming growth factor-beta activity in the microenvironment, prior treatment and tumor proliferative potential. Their association with CPI response and survival was observed across all tumor types and validated across six independent cohorts (n = 1,491). These five latent factors constitute a frame of reference to organize current and future knowledge on biomarkers of CPI response and survival., We wish to acknowledge the contribution of patients, families and biomedical researchers who shared, processed and sequenced the data used in the study. This publication and the underlying study have been made possible partly based on the data that HMF has made available. We also acknowledge the use of data from the INSPIRE clinical trial (NCT02644369) and data obtained from patients presented at the VHIO. N.L.-B. acknowledges funding from the European Research Council (ERC; consolidator grant 682398). This project has received funding from the European Union’s Horizon program HORIZON-HLTH-2021-CARE-05-02 for the project CGI-Clinics under grant agreement no. 101057509. E.B. receives support from Generalitat de Catalunya (2021 SGR 001278) and ERC Advanced Grant 884623. The Institute for Research in Biomedicine Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and an Excellence Institutional grant by the Asociacion Española contra el Cancer and is supported by CERCA (Generalitat de Catalunya).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Oncodrive3D: fast and accurate detection of structural clusters of somatic mutations under positive selection

  • Pellegrini, Stefano
  • Dove-Estrella, Olivia
  • Muiños, Ferran
  • López Bigas, Núria
  • González-Pérez, Abel
Identifying the genes capable of driving tumorigenesis in different tissues is one of the central goals of cancer genomics. Computational methods that exploit different signals of positive selection in the pattern of mutations observed in genes across tumors have been developed to this end. One such signal of positive selection is clustering of mutations in areas of the three-dimensional (3D) structure of the protein above the expectation under neutrality. Methods that exploit this signal have been hindered by the paucity of proteins with experimentally solved 3D structures covering their entire sequence. Here, we present Oncodrive3D, a computational method that, by exploiting AlphaFold 2 structural models, extends the identification of proteins with significant mutational 3D clusters to the entire human proteome. Oncodrive3D shows sensitivity and specificity on par with state-of-the-art cancer driver gene identification methods exploiting mutational clustering and clearly outperforms them in computational efficiency. We demonstrate, through several examples, how significant mutational 3D clusters identified by Oncodrive3D in different known or potential cancer driver genes can reveal details about the mechanism of tumorigenesis in different cancer types and in clonal hematopoiesis., This project has received funding from the European Union's Horizon Europe program HORIZON-HLTH-2021-CARE-05-02 for the project CGI-Clinics under grant agreement No. 101057509, and has also been supported by the PID2021-126568OB-I00 (CHEMOHEALTH) project, funded by the Spanish Ministry of Science (MCIN), AEI/10.13039/501100011033/. SP acknowledges the support of scholarship PRE2021-096986, funded by the Spanish Ministry of Science (MCIN)/AEI/10.13039/501100011033 and FSE. Funding to pay the Open Access publication charges for this article was provided by HORIZON-HLTH-2021-CARE-05-02 project funded by Horizon Europe.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker

  • Thorvaldsdottir, Birna
  • Espinet Solà, Blanca
  • Puiggros Metje, Anna Maria
  • Rosenquist, Richard
Despite the well-established adverse impact of del(11q) in chronic lymphocytic leukemia (CLL), the prognostic significance of somatic ATM mutations remains uncertain. We evaluated the effects of ATM aberrations (del(11q) and/or ATM mutations) on time-to-first-treatment (TTFT) in 3631 untreated patients with CLL, in the context of IGHV gene mutational status and mutations in nine CLL-related genes. ATM mutations were present in 246 cases (6.8%), frequently co-occurring with del(11q) (112/246 cases, 45.5%). ATM-mutated patients displayed a different spectrum of genetic abnormalities when comparing IGHV-mutated (M-CLL) and unmutated (U-CLL) cases: M-CLL was enriched for SF3B1 and NFKBIE mutations, whereas U-CLL showed mutual exclusivity with trisomy 12 and TP53 mutations. Isolated ATM mutations were rare, affecting 1.2% of Binet A patients and <1% of M-CLL cases. While univariable analysis revealed shorter TTFT for Binet A patients with any ATM aberration compared to ATM-wildtype, multivariable analysis identified only del(11q), trisomy 12, SF3B1, and EGR2 mutations as independent prognosticators of shorter TTFT among Binet A patients and within M-CLL and U-CLL subgroups. These findings highlight del(11q), and not ATM mutations, as a key biomarker of increased risk of early progression and need for therapy, particularly in otherwise indolent M-CLL, providing insights into risk-stratification and therapeutic decision-making., This work was in part supported by; Associazione Italiana per la Ricerca sul Cancro—AIRC, Milano, Italy (Investigator Grant #27566, P.I. Ghia Paolo) and Special Program on Metastatic Disease— 5 per mille #21198 program—P.I. Foà Roberto, G.L. Paolo Ghia, Gianluca Gaidano); ; “la Caixa” Foundation (Health Research 2017 Program HR17-00221); the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245), and the Lady Tata Memorial Trust (International Award for Research in Leukemia 2021- 2022, LADY_TATA_21_3223); the Hellenic Precision Medicine Network in Oncology; project ODYSSEAS (Intelligent and Automated Systems for enabling the Design, Simulation and Development of Integrated Processes and Products) implemented under the “Action for the Strategic Development on the Research and Technological Sector”, funded by the Operational Program “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014-2020) and co-financed by Greece and the European Union, with grant agreement no: MIS 5002462”; MHCZ—DRO (FNBr, 65269705), NV21-08-00237 and the project National Institute for Cancer Research (Program EXCELES, ID Project No. LX22NPO5102)—Funded by the European Union—Next- Generation EU; Instituto de Salud Carlos III (ISCIII), “PI21/00983”, co-funded by the European Union; Instituto de Salud Carlos III (ISCIII), “PI21/00983”, co- funded by the European Union; Fondo di Ateneo per la Ricerca (FAR) 2019, 2020 and 2021 of the University of Ferrara (GMR; AC), Associazione Italiana contro le Leucemie- Linfomi e Mieloma ONLUS Ferrara (AC; GMR), BEAT Leukemia Foundation Milan Italy (AC); the Danish Cancer Society and the CLL-CLUE project under the frame of ERA PerMed; Cancer Research UK (ECRIN-M3 accelerator award C42023/A29370, Southampton Experimental Cancer Medicine Center grant C24563/A15581, Cancer Research UK Southampton Center grant C34999/A18087, and program C2750/ A23669); the Swedish Cancer Society (22 2448 Pj), the Swedish Research Council (2020-01750), Region Stockholm (ALF/FoUI-962423), and Radiumhemmets Forskningsfonder (194133), Stockholm; CGI-Clinics, a European Union’s Horizon 2022-2027 program under grant agreement 101057509.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker

  • Thorvaldsdottir, Birna
  • Mansouri, Larry
  • Sutton, Lesley-Ann
  • Nadeu, Ferran
  • Meggendorfer, Manja
  • Parker, Helen
  • Brieghel, Christian
  • Laidou, Stamatia
  • Moia, Riccardo
  • Rossi, Davide
  • Kotaskova, Jana
  • Delgado, Julio
  • Rodríguez-Vicente, Ana Eugenia
  • Benito, Rocío
  • Rigolin, Gian Matteo
  • Bonfiglio, Silvia
  • Scarfò, Lydia
  • Mattsson, Mattias
  • Davis, Zadie
  • Baliakas, Panagiotis
  • Rapado, Inmaculada
  • Mirás, Fátima
  • Martínez-López, Joaquín
  • Serna, Javier de la
  • Hernández, Jesús M.
  • Larráyoz, María José
  • Calasanz, Mª Jose
  • Smedby, Karin E.
  • Espinet, Blanca
  • Puiggros, Anna
  • Bullinger, Lars
  • Bosch, Francesc
  • Tazón‐Vega, Bárbara
  • Baran-Marszak, Fanny
  • Oscier, David
  • Nguyen-Khac, Florence
  • Zenz, Thorsten
  • Terol, María José
  • Cuneo, Antonio
  • Hernández-Sánchez, María
  • Pospisilova, Sarka
  • Gaidano, Gianluca
  • Niemann, Carsten U.
  • Campo, Elías
  • Strefford, Jonathan C.
  • Ghia, Paolo
  • Stamatopoulos, Kostas
  • Rosenquist, Richard
Despite the well-established adverse impact of del(11q) in chronic lymphocytic leukemia (CLL), the prognostic significance of somatic ATM mutations remains uncertain. We evaluated the effects of ATM aberrations (del(11q) and/or ATM mutations) on time-to-first-treatment (TTFT) in 3631 untreated patients with CLL, in the context of IGHV gene mutational status and mutations in nine CLL-related genes. ATM mutations were present in 246 cases (6.8%), frequently co-occurring with del(11q) (112/246 cases, 45.5%). ATM-mutated patients displayed a different spectrum of genetic abnormalities when comparing IGHV-mutated (M-CLL) and unmutated (U-CLL) cases: M-CLL was enriched for SF3B1 and NFKBIE mutations, whereas U-CLL showed mutual exclusivity with trisomy 12 and TP53 mutations. Isolated ATM mutations were rare, affecting 1.2% of Binet A patients and <1% of M-CLL cases. While univariable analysis revealed shorter TTFT for Binet A patients with any ATM aberration compared to ATM-wildtype, multivariable analysis identified only del(11q), trisomy 12, SF3B1, and EGR2 mutations as independent prognosticators of shorter TTFT among Binet A patients and within M-CLL and U-CLL subgroups. These findings highlight del(11q), and not ATM mutations, as a key biomarker of increased risk of early progression and need for therapy, particularly in otherwise indolent M-CLL, providing insights into risk-stratification and therapeutic decision-making., This work was in part supported by; Associazione Italiana per la Ricerca sul Cancro—AIRC, Milano, Italy (Investigator Grant #27566, P.I. Ghia Paolo) and Special Program on Metastatic Disease— 5 per mille #21198 program—P.I. Foà Roberto, G.L. Paolo Ghia, Gianluca Gaidano); ; “la Caixa” Foundation (Health Research 2017 Program HR17-00221); the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245), and the Lady Tata Memorial Trust (International Award for Research in Leukemia 2021- 2022, LADY_TATA_21_3223); the Hellenic Precision Medicine Network in Oncology; project ODYSSEAS (Intelligent and Automated Systems for enabling the Design, Simulation and Development of Integrated Processes and Products) implemented under the “Action for the Strategic Development on the Research and Technological Sector”, funded by the Operational Program “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014-2020) and co-financed by Greece and the European Union, with grant agreement no: MIS 5002462”; MHCZ—DRO (FNBr, 65269705), NV21-08-00237 and the project National Institute for Cancer Research (Program EXCELES, ID Project No. LX22NPO5102)—Funded by the European Union—Next- Generation EU; Instituto de Salud Carlos III (ISCIII), “PI21/00983”, co-funded by the European Union; Instituto de Salud Carlos III (ISCIII), “PI21/00983”, co- funded by the European Union; Fondo di Ateneo per la Ricerca (FAR) 2019, 2020 and 2021 of the University of Ferrara (GMR; AC), Associazione Italiana contro le Leucemie- Linfomi e Mieloma ONLUS Ferrara (AC; GMR), BEAT Leukemia Foundation Milan Italy (AC); the Danish Cancer Society and the CLL-CLUE project under the frame of ERA PerMed; Cancer Research UK (ECRIN-M3 accelerator award C42023/A29370, Southampton Experimental Cancer Medicine Center grant C24563/A15581, Cancer Research UK Southampton Center grant C34999/A18087, and program C2750/ A23669); the Swedish Cancer Society (22 2448 Pj), the Swedish Research Council (2020-01750), Region Stockholm (ALF/FoUI-962423), and Radiumhemmets Forskningsfonder (194133), Stockholm; CGI-Clinics, a European Union’s Horizon 2022-2027 program under grant agreement 101057509., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Oncodrive3D: fast and accurate detection of structural clusters of somatic mutations under positive selection

  • Pellegrini, Stefano
  • Dove-Estrella, Olivia
  • Muiños, Ferran
  • López Bigas, Núria
  • González-Pérez, Abel
Identifying the genes capable of driving tumorigenesis in different tissues is one of the central goals of cancer genomics. Computational methods that exploit different signals of positive selection in the pattern of mutations observed in genes across tumors have been developed to this end. One such signal of positive selection is clustering of mutations in areas of the three-dimensional (3D) structure of the protein above the expectation under neutrality. Methods that exploit this signal have been hindered by the paucity of proteins with experimentally solved 3D structures covering their entire sequence. Here, we present Oncodrive3D, a computational method that, by exploiting AlphaFold 2 structural models, extends the identification of proteins with significant mutational 3D clusters to the entire human proteome. Oncodrive3D shows sensitivity and specificity on par with state-of-the-art cancer driver gene identification methods exploiting mutational clustering and clearly outperforms them in computational efficiency. We demonstrate, through several examples, how significant mutational 3D clusters identified by Oncodrive3D in different known or potential cancer driver genes can reveal details about the mechanism of tumorigenesis in different cancer types and in clonal hematopoiesis., This project has received funding from the European Union's Horizon Europe program HORIZON-HLTH-2021-CARE-05-02 for the project CGI-Clinics under grant agreement No. 101057509, and has also been supported by the PID2021-126568OB-I00 (CHEMOHEALTH) project, funded by the Spanish Ministry of Science (MCIN), AEI/10.13039/501100011033/. SP acknowledges the support of scholarship PRE2021-096986, funded by the Spanish Ministry of Science (MCIN)/AEI/10.13039/501100011033 and FSE. Funding to pay the Open Access publication charges for this article was provided by HORIZON-HLTH-2021-CARE-05-02 project funded by Horizon Europe.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Five latent factors underlie response to immunotherapy

  • Usset, Joseph
  • Rosendahl Huber, Axel
  • Andrianova, Maria A.
  • Batlle Gómez, Eduard
  • Carles, Joan
  • Cuppen, Edwin
  • Elez, Elena
  • Felip, Enriqueta
  • Gómez Rey, Marina
  • Lo Giacco, Deborah
  • Martínez Jiménez, Francisco
  • Muñoz Couselo, Eva
  • Siu, Lillian L.
  • Tabernero Cartula, Josep
  • Vivancos Prellezo, Ana
  • Muiños, Ferran
  • González-Pérez, Abel
  • López Bigas, Núria
Only a subset of patients treated with immune checkpoint inhibitors (CPIs) respond to the treatment, and distinguishing responders from non-responders is a major challenge. Many proposed biomarkers of CPI response and survival probably represent alternative measurements of the same aspects of the tumor, its microenvironment or the host. Thus, we currently ignore how many truly independent biomarkers there are. With an unbiased analysis of genomics, transcriptomics and clinical data of a cohort of patients with metastatic tumors (n = 479), we discovered five orthogonal latent factors: tumor mutation burden, T cell effective infiltration, transforming growth factor-beta activity in the microenvironment, prior treatment and tumor proliferative potential. Their association with CPI response and survival was observed across all tumor types and validated across six independent cohorts (n = 1,491). These five latent factors constitute a frame of reference to organize current and future knowledge on biomarkers of CPI response and survival., We wish to acknowledge the contribution of patients, families and biomedical researchers who shared, processed and sequenced the data used in the study. This publication and the underlying study have been made possible partly based on the data that HMF has made available. We also acknowledge the use of data from the INSPIRE clinical trial (NCT02644369) and data obtained from patients presented at the VHIO. N.L.-B. acknowledges funding from the European Research Council (ERC; consolidator grant 682398). This project has received funding from the European Union’s Horizon program HORIZON-HLTH-2021-CARE-05-02 for the project CGI-Clinics under grant agreement no. 101057509. E.B. receives support from Generalitat de Catalunya (2021 SGR 001278) and ERC Advanced Grant 884623. The Institute for Research in Biomedicine Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and an Excellence Institutional grant by the Asociacion Española contra el Cancer and is supported by CERCA (Generalitat de Catalunya).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

OpenVariant: a toolkit to parse and operate multiple input file formats

  • Martínez-Millán, David
  • Brando, Federica
  • Grau, Miguel L.
  • Sánchez-Guixé, Mònica
  • López Elorduy, Carlos
  • Reyes-Salazar, Iker
  • Deu-Pons, Jordi
  • López Bigas, Núria
  • González-Pérez, Abel
Summary: Advances in high-throughput DNA sequencing technologies and decreasing costs have fueled the identification of small genetic variants (such as single nucleotide variants and indels) across tumors. Despite efforts to standardize variant formats and vocabularies, many sources of variability persist across databases and computational tools that annotate variants, hindering their integration within cancer genomic analyses. In this context, we present OpenVariant, an easily extendable Python package that facilitates seamless reading, parsing and refinement of diverse input file formats in a customizable structure, all within a single process. Availability and implementation: OpenVariant is an open-source package available at https://github.com/bbglab/openvariant. Documentation may be found at https://openvariant.readthedocs.io., N.L.-B. acknowledges funding from the European Research Council [consolidator grant 682398]. This project has received funding from the European Union’s Horizon Europe programme [grant agreement CGI-Clinics 101057509]. IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and an Excellence Institutional grant by the Asociación Española contra el Cancer, and is supported by CERCA (Generalitat de Catalunya). This work has also been funded by the Institute of Health Carlos III [project IMPaCT-Data, exp. IMP/00019], co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Five latent factors underlie response to immunotherapy

  • Usset, Joseph
  • Huber, Axel Rosendahl
  • Andrianova, Maria A.
  • Batlle, Eduard
  • Lo Giacco, Deborah
  • Cuppen, Edwin
  • Gómez-Rey, Marina
  • Martínez-Jiménez, Francisco
  • MUÑOZ COUSELO, EVA
  • Tabernero, Josep
  • Vivancos, Ana
  • Carles, Joan
  • Elez, Elena
  • FELIP, ENRIQUETA
Response; Immunotherapy, Respuesta; Inmunoterapia, Resposta; Immunoteràpia, Only a subset of patients treated with immune checkpoint inhibitors (CPIs) respond to the treatment, and distinguishing responders from non-responders is a major challenge. Many proposed biomarkers of CPI response and survival probably represent alternative measurements of the same aspects of the tumor, its microenvironment or the host. Thus, we currently ignore how many truly independent biomarkers there are. With an unbiased analysis of genomics, transcriptomics and clinical data of a cohort of patients with metastatic tumors (n = 479), we discovered five orthogonal latent factors: tumor mutation burden, T cell effective infiltration, transforming growth factor-beta activity in the microenvironment, prior treatment and tumor proliferative potential. Their association with CPI response and survival was observed across all tumor types and validated across six independent cohorts (n = 1,491). These five latent factors constitute a frame of reference to organize current and future knowledge on biomarkers of CPI response and survival., This publication and the underlying study have been made possible partly based on the data that HMF has made available. We also acknowledge the use of data from the INSPIRE clinical trial (NCT02644369) and data obtained from patients presented at the VHIO. N.L.-B. acknowledges funding from the European Research Council (ERC; consolidator grant 682398). This project has received funding from the European Union’s Horizon program HORIZON-HLTH-2021-CARE-05-02 for the project CGI-Clinics under grant agreement no. 101057509. E.B. receives support from Generalitat de Catalunya (2021 SGR 001278) and ERC Advanced Grant 884623. The Institute for Research in Biomedicine Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and an Excellence Institutional grant by the Asociacion Española contra el Cancer and is supported by CERCA (Generalitat de Catalunya).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker

  • Thorvaldsdottir, Birna
  • Espinet Solà, Blanca
  • Puiggros Metje, Anna Maria
  • Rosenquist, Richard
Despite the well-established adverse impact of del(11q) in chronic lymphocytic leukemia (CLL), the prognostic significance of somatic ATM mutations remains uncertain. We evaluated the effects of ATM aberrations (del(11q) and/or ATM mutations) on time-to-first-treatment (TTFT) in 3631 untreated patients with CLL, in the context of IGHV gene mutational status and mutations in nine CLL-related genes. ATM mutations were present in 246 cases (6.8%), frequently co-occurring with del(11q) (112/246 cases, 45.5%). ATM-mutated patients displayed a different spectrum of genetic abnormalities when comparing IGHV-mutated (M-CLL) and unmutated (U-CLL) cases: M-CLL was enriched for SF3B1 and NFKBIE mutations, whereas U-CLL showed mutual exclusivity with trisomy 12 and TP53 mutations. Isolated ATM mutations were rare, affecting 1.2% of Binet A patients and <1% of M-CLL cases. While univariable analysis revealed shorter TTFT for Binet A patients with any ATM aberration compared to ATM-wildtype, multivariable analysis identified only del(11q), trisomy 12, SF3B1, and EGR2 mutations as independent prognosticators of shorter TTFT among Binet A patients and within M-CLL and U-CLL subgroups. These findings highlight del(11q), and not ATM mutations, as a key biomarker of increased risk of early progression and need for therapy, particularly in otherwise indolent M-CLL, providing insights into risk-stratification and therapeutic decision-making., This work was in part supported by; Associazione Italiana per la Ricerca sul Cancro—AIRC, Milano, Italy (Investigator Grant #27566, P.I. Ghia Paolo) and Special Program on Metastatic Disease— 5 per mille #21198 program—P.I. Foà Roberto, G.L. Paolo Ghia, Gianluca Gaidano); ; “la Caixa” Foundation (Health Research 2017 Program HR17-00221); the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245), and the Lady Tata Memorial Trust (International Award for Research in Leukemia 2021- 2022, LADY_TATA_21_3223); the Hellenic Precision Medicine Network in Oncology; project ODYSSEAS (Intelligent and Automated Systems for enabling the Design, Simulation and Development of Integrated Processes and Products) implemented under the “Action for the Strategic Development on the Research and Technological Sector”, funded by the Operational Program “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014-2020) and co-financed by Greece and the European Union, with grant agreement no: MIS 5002462”; MHCZ—DRO (FNBr, 65269705), NV21-08-00237 and the project National Institute for Cancer Research (Program EXCELES, ID Project No. LX22NPO5102)—Funded by the European Union—Next- Generation EU; Instituto de Salud Carlos III (ISCIII), “PI21/00983”, co-funded by the European Union; Instituto de Salud Carlos III (ISCIII), “PI21/00983”, co- funded by the European Union; Fondo di Ateneo per la Ricerca (FAR) 2019, 2020 and 2021 of the University of Ferrara (GMR; AC), Associazione Italiana contro le Leucemie- Linfomi e Mieloma ONLUS Ferrara (AC; GMR), BEAT Leukemia Foundation Milan Italy (AC); the Danish Cancer Society and the CLL-CLUE project under the frame of ERA PerMed; Cancer Research UK (ECRIN-M3 accelerator award C42023/A29370, Southampton Experimental Cancer Medicine Center grant C24563/A15581, Cancer Research UK Southampton Center grant C34999/A18087, and program C2750/ A23669); the Swedish Cancer Society (22 2448 Pj), the Swedish Research Council (2020-01750), Region Stockholm (ALF/FoUI-962423), and Radiumhemmets Forskningsfonder (194133), Stockholm; CGI-Clinics, a European Union’s Horizon 2022-2027 program under grant agreement 101057509.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Five latent factors underlie response to immunotherapy

  • Usset, Joseph
  • Huber, Axel Rosendahl
  • Andrianova, Maria A.
  • Batlle, Eduard
  • Lo Giacco, Deborah
  • Cuppen, Edwin
  • Gómez-Rey, Marina
  • Martínez-Jiménez, Francisco
  • MUÑOZ COUSELO, EVA
  • Tabernero, Josep
  • Vivancos, Ana
  • Carles, Joan
  • Elez, Elena
  • FELIP, ENRIQUETA
Response; Immunotherapy, Respuesta; Inmunoterapia, Resposta; Immunoteràpia, Only a subset of patients treated with immune checkpoint inhibitors (CPIs) respond to the treatment, and distinguishing responders from non-responders is a major challenge. Many proposed biomarkers of CPI response and survival probably represent alternative measurements of the same aspects of the tumor, its microenvironment or the host. Thus, we currently ignore how many truly independent biomarkers there are. With an unbiased analysis of genomics, transcriptomics and clinical data of a cohort of patients with metastatic tumors (n = 479), we discovered five orthogonal latent factors: tumor mutation burden, T cell effective infiltration, transforming growth factor-beta activity in the microenvironment, prior treatment and tumor proliferative potential. Their association with CPI response and survival was observed across all tumor types and validated across six independent cohorts (n = 1,491). These five latent factors constitute a frame of reference to organize current and future knowledge on biomarkers of CPI response and survival., This publication and the underlying study have been made possible partly based on the data that HMF has made available. We also acknowledge the use of data from the INSPIRE clinical trial (NCT02644369) and data obtained from patients presented at the VHIO. N.L.-B. acknowledges funding from the European Research Council (ERC; consolidator grant 682398). This project has received funding from the European Union’s Horizon program HORIZON-HLTH-2021-CARE-05-02 for the project CGI-Clinics under grant agreement no. 101057509. E.B. receives support from Generalitat de Catalunya (2021 SGR 001278) and ERC Advanced Grant 884623. The Institute for Research in Biomedicine Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and an Excellence Institutional grant by the Asociacion Española contra el Cancer and is supported by CERCA (Generalitat de Catalunya).